Hox Therapeutics Announces Collaboration with Vernalis

Overview

Hox Therapeutics Ltd a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd (""Vernalis""), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target. Under the terms of the agreement, Vernalis will use its state-of-the-art protein science and Hit ID platforms to produce the target protein, and to identify and characterise small molecule inhibitors of the target. The research at Vernalis will be funded by Hox. Financial terms have not been disclosed.

Words from Vernalis

James Murray, Research Director of Vernalis, said, ""This partnership is built on Vernalis's strong record for innovation in drug discovery to generate clinical candidates. We look forward to working closely with Hox to successfully achieve the goals of this collaboration"".

CEO from Hox Therapeutics

Nicholas Adams, CEO of Hox Therapeutics, said, ""We are delighted to be working with Vernalis on this project. They have proven expertise in being able to identify inhibitors against the protein target that we're interested in"".

About Hox Therapeutics Ltd

Hox Therapeutics is a preclinical-stage biotechnology company focused on the discovery and development of innovative, highly targeted medicines for the treatment of cancer.

About Vernalis

• Vernalis is a world leader in fragment and structure-based drug discovery with a record of progressing targets from concept to clinic. 

• Based in Cambridge, UK, we have generated development candidates across oncology, neurodegeneration, anti-infectives and inflammation, through global collaborations. 

• Vernalis is a wholly owned subsidiary of HitGen Inc (688222.SH).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!